HomeAI · summaries
Storia in 4 fonti
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
When Belén Garijo, M.D., Ph.D., left the top job at Germany’s Merck KGaA to head over to Sanofi, she was inheriting a company in need of course correction. | Sanofi's new CEO Belén Garijo opened up for the first time about her strategy to reverse a trend of clinical setbacks, including dumping Regeneron-partnered IL-33 candidate itepekimab.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercebiotech.com
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
When Belén Garijo, M.D., Ph.D., left the top job at Germany’s Merck KGaA to head over to Sanofi, she was inheriting a company in need of course correction. | Sanofi's new CEO…
- ·
faz.net
Sanofi: Belén Garijo setzt auf Innovation und Wachstum
Belén Garijo hat deutlich gemacht, dass unter ihrer Führung bei Sanofi ein neuer Wind weht. Die Erwartungen sind groß, die Konkurrenz aber enteilt.
